Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis

the research work was conducted for the pharmacoeconomic evaluation and optimization of fluid therapy for patients, suffering from peritonitis disease. Reamberin, Ringer's solution, Plasma-Lyte and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis...

Full description

Bibliographic Details
Main Authors:	R. I. Yagudina, M. M. Murashko
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	pharmacoeconomics cost analysis an analysis of the “cost-effectiveness” analysis of the “impact on the budget” peritonitis reamberin
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/46

Similar Items

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy
by: I. N. Dyakov, et al.
Published: (2021-02-01)

COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01)

Evaluation of the pharmacoeconomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program
by: I N Dyakov, et al.
Published: (2016-11-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
by: A. V. Rudakova, et al.
Published: (2021-07-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS
by: M. V. Protsenko
Published: (2015-03-01)

COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
by: M. B. Kubaeva, et al.
Published: (2017-08-01)

RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01)

Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: Pharmacoeconomic aspects
by: V V Riazhenov, et al.
Published: (2014-02-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Pharmacoeconomic analysis of cost-benefit in evaluating the effectiveness of treatment for epilepsy in adults
by: P. N. Vlasov, et al.
Published: (2010-06-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective
by: Yagudina R, et al.
Published: (2021-07-01)

Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Comparative pharmacoeconomic analysis of posaconazole therapy in tablet form and in suspension for invasive fungal infections prevention
by: I. S. Krysanov, et al.
Published: (2021-06-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA
by: Elena Albertovna Sobko, et al.
Published: (2015-09-01)

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia
by: Sergey V. Nedogoda, et al.
Published: (2021-12-01)

Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China
by: Chen Yu, et al.
Published: (2018-03-01)

PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY
by: D. D. Morikov, et al.
Published: (2017-04-01)

Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment
by: A. U. Kulikov, et al.
Published: (2015-03-01)

Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma
by: A S Kolbin, et al.
Published: (2019-12-01)

Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation
by: R. I. Yagudina, et al.
Published: (2022-04-01)

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation
by: S. K. Zyryanov, et al.
Published: (2020-02-01)